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TP53 mutations are associated with adverse outcomes and shorter response to
hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have
evaluated the impact of the type, number, and patterns of TP53 mutations in response
outcomes and prognosis of MDS. We evaluated the clinicopathologic characteristics,
outcomes, and response to therapy of 261 patients with MDS and TP53 mutations. Median
age was 68 years (range, 18-80 years). A total of 217 patients (83%) had a complex karyotype.
TP53 mutations were detected at a median variant allele frequency (VAF) of 0.39 (range,
0.01-0.94). TP53 deletion was associated with lower overall response rate (ORR) (odds ratio,
0.3; P 5 .021), and lower TP53 VAF correlated with higher ORR to HMAs. Increase in TP53
VAF at the time of transformation was observed in 13 patients (61%), and previously
undetectable mutations were observed in 15 patients (65%). TP53 VAF was associated with
worse prognosis (hazard ratio, 1.02 per 1% VAF increase; 95% confidence interval, 1.01-1.03;
P , .001). Integration of TP53 VAF and karyotypic complexity identified prognostic
subgroups within TP53-mutant MDS. We developed a multivariable model for overall
survival that included the revised International Prognostic Scoring System (IPSS-R)
categories and TP53 VAF. Total score for each patient was calculated as follows: VAF TP531
13 3 IPSS-R blast score 1 16 3 IPSS-R cytogenetic score 1 28 3 IPSS-R hemoglobin score 1
46 3 IPSS-R platelet score. Use of this model identified 4 prognostic subgroups with median
survival times of not reached, 42.2, 21.9, and 9.2months. These data suggest that outcomes of
patients with TP53-mutated MDS are heterogeneous and that transformation may be driven
not only by TP53 but also by other factors.
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by
ineffective hematopoiesis leading to cytopenias and risk of transformation to acute myeloid leukemia
(AML).1 Mutations in TP53 are observed in 10% to 12% of patients with MDS and are associated with
adverse outcomes, risk of transformation to AML, and shorter response to current available therapies.2-8
Although most TP53 mutations occur within the DNA-binding domain (DBD), mutations can be
observed throughout the whole gene length.2,9-12 Recent studies suggest the clonal size of TP53
mutations, determined by the variant allele frequency (VAF), may influence prognosis.4,13 Preclinical
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models suggest that distinct mutation types in different TP53 gene
domains may lead to different impacts on protein functionality.14-17
Whether these functional differences translate into distinct clinical
features and outcomes and how the type, number, and size of TP53
mutations influence the prognosis of patients with TP53-mutated
MDS remains unclear, so it has become necessary to determine
whether additional disease characteristics such as karyotypic
abnormalities or additional gene mutations influence prognosis in
this group of patients. In addition, although TP53 mutations are
known to predict for transformation to AML, the specific clonal
changes that lead to transformation to AML in TP53-mutant MDS
are not fully understood.
In this study, we evaluated the TP53 and comutational patterns and
characteristics of a cohort of 938 patients with MDS, including 261
patients with TP53 mutations. We evaluated the patterns of TP53
mutations, other mutated genes, and TP53 deletions and corre-
lated them with clinical outcomes to determine whether specific




We evaluated all consecutive patients with previously untreated
MDS who were treated at The University of Texas MD Anderson
Cancer Center (MDACC) from 2013 to 2018. Informed consent
was obtained according to protocols approved by the MDACC
Institutional Review Board in accordance with the Declaration of
Helsinki. Diagnosis was confirmed in the hematopathology labora-
tory at MDACC by morphologic, cytochemical, and immunohisto-
chemical analysis using the World Health Organization (WHO)
2008 and 2016 criteria.18 Conventional karyotyping was performed
on fresh bone marrow (BM) aspirate using standard procedures
and reported by using the International System for Human
Cytogenetic Nomenclature 2013.19 Prognostic risk was calculated
using both the International Prognostic Scoring System (IPSS)20
and the revised IPSS (IPSS-R)21 for patients with MDS.
Targeted gene sequencing analysis
Genomic DNA was extracted from whole BM aspirate samples and
was subjected to targeted polymerase chain reaction–based
sequencing using a next-generation sequencing platform as pre-
viously described.22 This analysis was performed within the MDACC
Clinical Laboratory Improvement Amendments–certified Molecular
Diagnostics Laboratory after informed consent (additional details in
the supplemental Data). For next-generation sequencing–based
analysis, the limit of detection for variant calling was 2%. Previously
described somatic mutations registered at the Catalogue of Somatic
Mutations in Cancer (COSMIC: http://cancer.sanger.ac.uk/cosmic)
were considered as potential driver mutations.
Determination of deletion of TP53 based on
conventional karyotyping
To evaluate the presence of TP53 locus deletion, all patients had
conventional karyotyping performed on unsorted BM. For cases of
chromosome 17 alteration in cytogenetics that usually result in
TP53 loss, fluorescence in situ hybridization (FISH) may or may
not have been performed. For cases involving balanced changes
involving breakpoint at 17p13, FISH was required to confirm or
exclude a TP53 deletion. Deletion of TP53 was counted as present
in the following cytogenetic alterations: monosomy 17; isochromo-
some i(17)(q10); del(17)(pvar(variable)) with pvar centromeric to
p13.1; unbalanced translocations, including der(var)t(var;17)(var;
qvar),–17; der(var)t(var;17)(var;pvar),–17 with pvar centromeric to
p13.1; der(17)t(17;var)(pvar;var)der(17)t(var;17)(var;pvar) with pvar
centromeric to p13.1; der(var)t(var;17)(var;qvar) with dicentric der;
der(var)t(var;17)(var;pvar) with pvar centromeric to p13.1 and dicentric
der; balanced translocation and 17p13 breakpoint: t(17;var)(p13;var)
or t(var;17)(var;p13) in the presence of TP53 deletion by FISH;
additive material: add(17)(pvar) in the presence of TP53 deletion by
FISH; dicentric chromosome dic(var;17)(var;pvar); and ring chromo-
some r(17)(pvarqvar) with the presence of TP53 deletion by FISH.
Statistical analysis and response assessment
Response assessment was performed by following 2006 Interna-
tional Working Group criteria.23 Response assessment included BM
aspiration after cycle 1 of therapy in all patients followed by sequential
BM aspirations every 1 to 3 months. Generalized linear models were
used to study the association of overall response rate (ORR),
complete remission (CR), and risk factors. Overall survival (OS) was
calculated as the number of months from diagnosis to death or last
follow-up date. Transformation-free survival (TFS) was defined as the
time interval between diagnosis and date of transformation or death.
Relapse-free survival (RFS) was calculated from the time of response
until relapse or death in response. Patients who were alive at their last
follow-up were censored on that date. The Kaplan-Meier product limit
method24 was used to estimate the median OS, TFS, and RFS for
each clinical or demographic factor. Univariable Cox proportional
hazards regression was used to identify any association with each of
the variables and survival outcomes.
Results
Patient characteristics
A total of 938 patients with MDS were evaluated during the
reviewed time period. Among these, a total of 261 (28%) had
detectable TP53 mutations. Patient characteristics are summarized
in Table 1. Among patients with TP53-mutant MDS, 8 (3%) were
classified as very-low risk (VL), 17 (7%) as low risk (L), 18 (7%) as
intermediate risk (Int), 48 (18%) as high risk (H), and 170 (65%) as
very-high risk (VH) by IPSS-R. Twenty patients (2%) met criteria for
MDS with isolated del(5q) of whom 10 (50%) received therapy with
lenalidomide, 3 (15%) with hypomethylating agents (HMAs), 3
(15%) with erythropoietin-stimulating agents, and 4 (20%) were on
observation. A total of 138 patients (53%) had therapy-related MDS
(T-MDS) related to therapy for previous malignancies, which
included chemotherapy in 131 patients (50%) and radiation therapy
in 70 patients (27%). Treatment data were available for a total of
201 patients (77%), with the remaining not having available
treatment and response data because of loss to follow-up or
therapy at an outside institution. Patients who did not receive
therapy at our institution were older (median age, 70 vs 68 years;
P 5 .034), more frequently female (73% vs 57%; P 5 .025), and
had a higher frequency of VL or L risk by IPSS-R (VL: 10% vs 1%, L:
17% vs 4%; P , .001) and higher frequency of good cytogenetic
features by IPSS-R (22% vs 7%; P 5 .003) than patients who did
receive therapy at MDACC. Characteristics of patients for which no
data on therapy were available are provided in supplemental Table 1.
First-line therapy in these patients was chemotherapy-based in 4
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patients (2%), single-agent HMAs in 121 patients (60%) (azaciti-
dine in 37 [30%], decitabine in 55 [45%], and guadecitabine in 29
[24%]), HMA in combination with novel agents in 73 patients
(36%), and immunomodulatory drugs in 1 patient. A total of 39
patients (15%) underwent allogeneic stem-cell transplantation (allo-
SCT), including 2 patients who underwent allo-SCT directly after
diagnosis with no pretransplantation therapy.
Landscape and characteristics of TP53 mutations and
other identified co-mutations
A total of 396 mutations in TP53 were detected with a median VAF
of 39% (range, 1% to 94%). Mutations included 309 (78%)
missense, 28 (7%) nonsense, 37 (9%) frameshift insertions or
deletions, and 18 (5%) splice-site mutations. The most prevalent
mutation was R273H (n5 18; 0.05%) followed by R248W (n5 14;
0.04%), Y220C (n 5 16; 0.04%), and R175H (n 5 13; 0.03%).
Locations of all identified mutations are shown in Figure 1A. Most
evaluated patients (n5 175; 67%) had 1, 75 (29%) had 2, 10 (4%)
had 3, and 1 (0.4%) had 4 detectable TP53 mutations. All but 1
patient had at least 1 missense mutation affecting the DBD.
Patterns of co-mutation indicating type of mutation are shown in
supplemental Figure 1. There was no difference in TP53 mutation
VAF among patients with T-MDS and de novo MDS (P 5 .35).
A total of 94 patients (37%) had detectable mutations in genes
other than TP53. The most frequently mutated gene was TET2
present in 15% of patients, followed by DNMT3A in 11% and
ASXL1 and SF3B1 in 7%. Frequency and VAF of identified
mutations are shown in Figure 1B. We studied the association of
Table 1. Clinical characteristics of patients who have MDS with TP53 mutations
Characteristic
TP53-mutant MDS (n 5 261) TP53-wildtype MDS (n 5 677)
Pn % Median Range n % Median Range
Median age, y 68 18-90 67 22-93 .770
Male sex 157 61 444 67 .101
Hemoglobin, g/dL 9.2 8.9-9.4 12 7.9-16.1 .408
WBC, 3 109/L 3.7 3.4-4.1 4.1 3.8-4.3 .211
Platelets, 3 109/L 84 73-95 130 122-139 ,.001
ANC, 3 109/L 1.9 1.6-2.1 2.2 2.0-2.4 .023
Median BM blast % 6 0-18 3 0-19 ,.001
WHO MDS diagnosis ,.001
Single lineage dysplasia 16 6 41 6
Multilineage dysplasia 52 20 212 31
Ring sideroblasts 22 8 101 15
Excess blasts 150 58 266 39
Unrecognized 15 6 42 6
del(5q) 5 2 15 2
Not available 0 0 1 0
IPSS-R risk category ,.001
Very low 8 3 88 13
Low 17 7 217 32
Intermediate 18 7 88 24
High 48 18 124 19
Very high 170 65 78 12
Not available 0 0 8
IPSS-R cytogenetic group ,.001
Very good 3 1 18 3
Good 27 10 423 63
Intermediate 6 2 113 17
Poor 7 3 55 8
Very poor 218 84 60 9
Complex karyotype 217 83 60 9 ,.001
Therapy related 138 53 91 13 ,.001
Prior chemotherapy 131 50 80 12
Prior radiation 70 27 58 9
ANC, absolute neutrophil count; WBC, white blood cell count.

















































































































































































































Figure 1. Landscape of identified TP53 mutations and other co-mutations. (A) Lollipop plot representing all identified mutations in TP53. Height of bar plot represents
frequency of a specific mutation. Color of each mutation (circles) represents mutation type. Color of each gene region represents domains. (B) Frequency of identified
mutations in other genes by amplicon-based next-generation sequencing. VAFs of identified mutations with median and range. Mutations are ordered by decreasing median
VAF. (C) Frequencies of TP53 mutation, TP53 deletion, and complex karyotype among the entire patient cohort (n 5 938).
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specific mutations present in at least 5 patients with the presence of
other mutations (supplemental Table 3). Substitution of arginine
with tryptophan in amino acid position 273 (R273C) tended to be
observed in the presence of mutations in other sequenced genes
(odds ratio [OR], 6.48; P 5 .076).
Karyotypic abnormalities and their associations with
TP53 mutations
The presence of a complex karyotype was associated with the
presence of a TP53 mutation (complex karyotype 78.3% vs non-
complex karyotype 6.7%;P, .001). TP53mutations in patientswithout
a complex karyotype included 55 missense mutations, nonsense
mutations in 2 patients (4%), and frameshift mutations in 2 patients
(4%); they affected the DBD in all but 2 patients in whom the mutation
was located in the topologically associating domain. In addition, the
VAF of TP53 mutations in patients without a complex karyotype was
significantly lower than in those with karyotypic complexity (median,
5.1% [range, 1%-58.4%] vs 33.9% [range, 0%-93.6%]; P , .001).
A total of 20 patients (2%) met the criteria for MDS with isolated
del(5q) based on WHO classification. Among these, 5 patients
(20%) had TP53 mutations, including 2 patients with 1 detectable
mutation (Y107X [VAF5 58.4%] and R248Q [VAF5 25.9%]) and
3 patients with 2 detectable TP53 mutations (Y220C [VAF 5
2.3%] and A138T [VAF5 23.2%] and Y163C [VAF5 14.6%] and
P152Q [VAF 5 10.7%]).
TP53 deletions were significantly more frequent among patients with
mutated TP53 compared with those with wild-type TP53 (31.8% vs
2.2%; P , .001), even among patients with complex karyotype
(37.3% vs 18.3%; P5 .005). Frequencies of co-occurrence of TP53
mutations, TP53 deletion, and complex karyotype are shown in
Figure 1C. Patients with T-MDS were more likely to have complex
karyotype (OR5 5.45; P, .0001) and have a TP53mutation (OR5
6.15; P, .0001). In patients with TP53-mutated MDS, there were no
differences in the frequency of TP53 deletions (33.3% vs 30.1%; P5
.573) or complex karyotype (84.8% vs 81.3%; P 5 .453) between
patients with T-MDS and de novo MDS. Among patients with TP53
mutations, those with more than 1 detectable mutation were less likely
to have TP53 deletions (9.3% vs 42.9%; P , .001).
To determine whether this could be associated with biallelic loss of
TP53 among double-TP53 mutants, we assessed TP53 dynamics
in 18 patients with multiple TP53 mutations for whom longitudinal
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Figure 2. Influence of TP53 mutation VAF in
response and dynamic changes of TP53 VAF
throughout therapy. (A) Percentage change in
TP53 mutation VAF before and after therapy in
patients with and without a clinical response to
HMA therapy. (B) TP53 VAF before and at the time
of response assessment in patients with and without
clinical response to HMA therapy. (C) Time-
dependent changes of TP53 VAF among 64
patients with multiple sequencing time points
throughout the course of therapy, including re-
sponse assessment, disease progression, trans-
formation, or relapse. Gray lines represent changes
in a specific patient; blue lines represent tendencies
of the entire evaluable cohort.
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patients, dynamics of both TP53 mutations throughout therapy,
response, and relapse suggested that both could be present within
the same clone in 8 patients (44%).
TP53 mutation VAF and TP53 deletion influence
response outcomes with HMA therapy
With a median follow-up of 21.9 months (95% confidence interval
[CI], 20.3-25.6 months), in contrast with previous studies,25 there
were no significant differences in ORR (58% vs 63%; P5 .303) or
CR (27% vs 22%; P 5 .288) based on the presence of TP53
mutation in patients treated with HMAs. Among patients treated
with single-agent HMAs, a trend to higher ORR was observed in
patients treated with guadecitabine compared with azacitidine or
decitabine (62% with guadecitabine, 49% with azacitidine, and
40% with decitabine; P 5 .419), with no significant differences in
CR rates (28%with guadecitabine, 22%with azacitidine, and 16%with
decitabine; P 5 .739). Schedules of HMA therapy are detailed in
supplemental Table 2. The presence of TP53 deletion was associated
with lower ORR (OR, 0.53; P 5 .021). Lower TP53 mutation VAF
correlated with higher ORR, but there were no differences in CR rate or
response duration based on VAF (supplemental Figure 3). There was
a trend for higher TP53 VAF to be associated with shorter response
duration (hazard ratio [HR], 1.007; 95% CI, 0.999-1.015; P 5 .099)
even when corrected for IPSS-R. In addition, there was no correlation
between the number of TP53 mutations and TP53 abnormalities with
ORR or CR, but the presence of 1 or more TP53 abnormalities was
associated with shorter response duration (median response duration,
not reached for no TP53 mutation vs 14.8 months if there was 1 TP53
mutation [HR, 2.51; 95% CI, 1.23-5.11; P5 .011] and 14.7 months if
there were 2 or more TP53 mutations [HR, 2.9; 95% CI, 1.64-5.13;
P , .001) (supplemental Figure 4).
Longitudinal sequencing throughout the course of therapy was
available in 64 patients with TP53-mutated disease. The clonal
size of the TP53 mutation, determined by VAF, decreased
more among responders than among nonresponders (P 5 .022)
with subsequent increase of VAF at the time of relapse
(Figure 2).
Cytogenetic evolution and mutational dynamics
during transformation to AML
Among the 261 patients with TP53-mutant MDS, 63 (24%)
experienced transformation to AML with a median TFS of
10.6 months (95% CI, 8.8-12.3 months). Univariable analysis
identified the number of TP53 mutations (HR, 2.03; 95% CI,
1.3-3.05; P, .001), TP53 mutation VAF (HR, 1.02 increase per
1% VAF increase over a VAF of 0%; 95% CI, 1.01-1.02;
P , .001), presence of TP53 deletion (HR, 2.10; 95% CI, 1.38-
3.19; P , .001), and the presence of complex karyotype (HR,
2.58; 95% CI, 1.70-3.91; P , .001) as predictors of shorter
TFS. By multivariable analysis that included these factors and
IPSS-R, only TP53 mutation VAF remained an independent
predictor of shorter TFS (HR, 1.02 increase per 1% VAF
increase; 95% CI, 1.00-1.03; P 5 .005). On the basis of
a Martingale residual analysis,26 the relationship between TP53
VAF and AML transformation risk remained linear at all TP53
VAF levels.
Sequencing data at the time of transformation was available in
23 (37%) of 63 patients who experienced transformation,
including 9 patients (39%) with T-MDS and 14 patients (61%)
with de novo MDS. Increase in TP53 VAF was observed in 5
patients (56%) with T-MDS and 8 patients (57%) with de novo
MDS (P 5 .940). Acquisition of new previously undetectable
mutations was observed in 5 patients (56%) with T-MDS and in 7
patients (50%) with de novo MDS (P 5 .675). New recurrent
cytogenetic abnormalities were observed in 13 patients (57%)
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Figure 3. Mutation and cytogenetic changes at the
time of transformation. Frequency of TP53 mutation
expansion represents percentage of patients with in-
crease in VAF of TP53 mutation at the time of trans-
formation among evaluable patients (n 5 23).
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was not driven by expansion of the TP53 mutant clone (n 5 10),
acquisition of previously undetectable mutations was observed in 5
patients (50%) with acquisition of inv(3), monosomy 7, and monosomy
17 in 1 patient each. Detailed mutational and cytogenetic changes at
the time of MDS diagnosis and transformation in patients with de novo












































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Cytogenetic evaluation and next-generation sequencing at baseline and time of transformation to AML. For each section of the figure, the upper graph
represents VAF of detectable mutations at the time of diagnosis of MDS and at transformation. Lower graphs represent gain (blue) or loss (red) of chromosomal material and
translocations (thin black lines connecting chromosomes) present at diagnosis or transformation. A partial semicircle present in the upper right corner of sexual chromosomes
in some patients represents marker chromosomes. Inversions or derivatives are shown in green.
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TP53 mutation VAF and cytogenetic complexity
define specific prognostic subgroups within
TP53-mutated MDS
By univariable analysis, the presence of TP53 mutation (HR, 4.8;
95% CI, 3.9-6.1; P , .001), TP53 deletion (HR, 3.7; 95% CI, 2.9-
4.9; P , .001), or complex karyotype (HR, 5.0; 95% CI, 4.0-6.3;
P , .001) were associated with adverse prognosis (Figure 5A;
supplemental Figure 5). No differences in survival were observed on
the basis of the type of TP53 mutation (supplemental Figure 6). A
nonsignificant trend to worse outcomes in patients with mutations
not involving DBD was observed (supplemental Figure 7). Among
patients with MDS with isolated del(5q), the presence of a TP53
mutation was not associated with significantly shorter survival
(median OS, 22.1 vs 28.1 months; HR, 4.61; 95% CI, 0.60-35.25;
P 5 .140). Among patients with TP53-mutant MDS, the presence
of a JAK2 mutation was associated with worse outcomes (HR,
4.38; 95% CI, 1.36-14.1; P 5 .013) with no other co-occurring
mutations influencing survival. The presence of 2 or more TP53
abnormalities, determined by the number of mutations and the
presence of TP53 deletion, was associated with shorter survival
(HR, 1.39; 95% CI, 1.03-1.89; P 5 .034; Figure 5B). In addition,
TP53 VAF was associated with worse prognosis (HR, 1.02 per 1%
VAF increase; 95% CI, 1.01-1.03; P, .001), and patients could be
classified into 3 distinct prognostic groups on the basis of their
TP53 VAF (Figure 5C). Integration of TP53 VAF and karyotypic
complexity was able to distinguish prognostic subgroups within
patients with TP53-mutant MDS (Figure 5D; supplemental Fig-
ure 8). Furthermore, no significant survival differences could be
observed among patients with wild-type TP53 and those with TP53
VAF ,10% in the absence of a complex karyotype (median OS,
13.6 vs 27 months; HR, 1.77; 95% CI, 0.90-3.50; P 5 .10;
supplemental Figure 9), even when corrected by IPSS-R category
(supplemental Table 2).
Allo-SCT was associated with improved OS (median OS, 14.4 vs
10.7 months; HR, 0.57; 95% CI, 0.37-0.87; P 5 .01), even among
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HR, 0.53; 95% CI, 0.35-0.82; P 5 .004). TP53 mutation VAF
trended toward being associated with worse OS (HR, 1.02 per 1%
VAF increase; 95% CI, 0.99-1.04; P 5 .098). Although a trend to
improved survival was observed for all groups (supplemental
Figure 10), improved OS with transplantation was statistically
significant only among patients with TP53 VAF of 20% to 50%,
although the difference was marginal (median OS, 14.2 vs 11.5
months; P5 .046). Among patients with wild-type TP53, a total of 118
patients (17%) underwent allo-SCT (VL, 7 [8%] of 88; L, 26 [12%] of
217; Int, 35 [22%] of 162; H, 24 [19%] of 124; VH, 26 [33%] of 78).
When corrected by IPSS-R category, transplantation was associated
with improved OS (HR, 0.62; 95% CI, 0.42-0.91; P 5 .015) with the
main benefit being observed in H patients (median OS, not reached vs
25 months; P 5 .044) by IPSS-R category.
To further evaluate the prognostic effect of TP53 mutation character-
istics, we performed a multivariable Cox proportional hazards model for
OS. The following patient characteristics were independently
associated with shorter OS (Table 2): TP53 VAF, IPSS-R BM blast
percentage, and cytogenetic, hemoglobin, and platelet categories.
The clonal size (VAF) of TP53 mutation was included as
a continuous variable, and all other variables were categorical.
Further analysis indicated no statistically significant interaction
between TP53 VAF and the IPSS-R score in predicting OS (P. .1),
demonstrating that an additive model is appropriate. The fitted
0








































































































































































Figure 5. Prognostic subgroups of patients with TP53-mutant MDS based on TP53 VAF and karyotype. Kaplan-Meier estimate curves for OS of patients based on
the presence of TP53 mutation, complex karyotype, and TP53 deletion (A); the number of TP53 abnormalities defined as the sum of mutations and deletions (B); VAF of TP53
mutation (C); and VAF of TP53 mutation and presence of a complex karyotype (D). CCG, complex cytogenetics; LOH, loss of heterozygosity.
Table 2. Multivariable analysis for OS
Variable HR 95% CI P
TP53 VAF 1.018 1.010-1.025 ,.001
One TP53 mutation 1.25 0.78-2.00 .35
Multiple TP53 mutations 1.39 0.88-2.19 .15
TP53 deletion 0.95 0.68-1.32 .75
IPSS-R category
Absolute neutrophil count 0.78 0.47-1.30 .35
BM blast count 1.32 1.18-1.47 ,.001
Cytogenetic risk category 1.32 1.17-1.50 ,.001
Hemoglobin 1.72 1.39-2.12 ,.001
Platelets 2.55 1.92-3.40 ,.001
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multivariable Cox model was validated by 10-fold cross-validation,
with a corrected concordance index of 0.81, demonstrating a strong
model fit. This model was used to generate a nomogram for OS
(Figure 6A). This nomogram provides a visual depiction of the relative
contribution of each prognostic factor to the total point score and the
weight of factors influencing survival. The formula for calculating the
total point score is as follows: total score5 VAF TP531 133 IPSS-R
blast score 1 16 3 IPSS-R cytogenetic score 1 28 3 IPSS-R
hemoglobin score 1 46 3 IPSS-R platelet score. Total point scores
ranged from 0 to 277.1, with a median of 89.4. Median survival times
for the 4 groups (lowest to highest score) were not reached, 42.2,
21.9, and 9.2 months (Figure 6B). We then performed multivariable
Cox proportional hazards models for RFS and TFS and developed
similar nomograms (supplemental Figures 11 and 12).
Discussion
Mutations in TP53 are associated with dismal prognosis and short
response durations to currently available therapies.3,9,10 Current
preclinical studies suggest that not all TP53 mutations are equal
and that cellular and genomic context may define biological
functions of mutant TP53.16,17 In addition, clonal size of TP53
mutations may define outcomes and prognosis of patients with
these mutations.4 In this study, we evaluated a cohort of 261
patients with MDS and TP53 mutations within a cohort of 938
patients with MDS. As a result of the high number of referrals for
T-MDS in our center, our study population included a higher than
expected frequency of TP53-mutated MDS.7,9,11 By studying this
cohort, we were able to identify that the presence of a complex
karyotype affects the outcomes of patients with TP53mutation, and
we observed that the clonal size of TP53 mutations influences
response to therapy with HMAs, risk of transformation to AML, and
OS, even when corrected by clinically relevant parameters such as
those included in the IPSS-R categories.
Although previous studies have reported the prognostic impact of
TP53 mutations and the distribution and type of mutations in
MDS,4,7,27 so far, there is no consistent analysis evaluating the
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Figure 6. Multivariable Cox proportional hazards
model and nomogram for OS. (A) Nomogram for
OS. Nomogram used by totaling points identified at top
scale for each of the independent variables. This
summed point score was then identified on a total
point scale to identify the 3-month and 1-year survival
probability and median OS. (B) Kaplan-Meier estimate
curves for OS, which were based on the 4 groups
determined by the median point score of the
multivariable model.
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potential associations of different co-occurring TP53 mutations or
of specific TP53 mutations with other commonly recurrent
mutations in MDS. In this study, 33% of patients with TP53
mutations had multiple detectable TP53 mutations. In all but 1
patient, 1 of the detectable mutations always involved a missense
mutation within the DBD. In addition, frequency of nonsense,
frameshift, or splice-site mutations was higher in patients with multiple
TP53 mutations compared with those with a single TP53 mutation.
Although this observation may be a result of the overall higher
frequency of missense mutations in the DBD, it could also indicate
unequal leukemogenic potential of these mutations. Further investiga-
tion into the potential distinct biological effects and leukemogenic
potential of these less frequent mutations is warranted.
To evaluate the prognostic and predictive impact of TP53
abnormalities and determine whether distinct prognostic subgroups
can be identified within patients with TP53-mutated MDS, we
studied the association of TP53 mutations with co-occurring
mutations, TP53 deletion, and the clonal size of TP53 mutations.
Although prognostic risk scores such as the IPSS-R were not
specifically developed for patients with T-MDS (who are known to
have significantly worse outcomes than patients with de novo
MDS), previous studies suggest that use of prognostic scores may
still be able to identify prognostic subsets in the group of patients
with T-MDS.28-30 Therefore, we decided to include the IPSS-R
categories as prognostic categories within our survival analysis. By
doing so, we were able to observe that TP53 mutation VAF and the
presence of karyotypic complexity can clearly stratify patients with
MDS into distinct prognostic subgroups, even when correcting by
clinical parameters and IPSS-R score, and we developed a nomo-
gram to predict expected median OS from the time of diagnosis.
We also identified that the number of TP53 abnormalities may
define the prognosis of these patients and that, as previously
reported, the type of TP53 mutation does not seem to have an
impact on prognosis.7 However, contrary to previous reports, which
suggest that TP53 mutations may identify prognostic subgroups
within groups of patients with complex karyotypes,7 we observed
that the presence of a complex karyotype may define prognostic
subgroups within patients with TP53 mutations. In addition, we
could identify a subset of patients with low mutation burden (TP53
VAF ,10%) and the absence of a complex karyotype whose
outcomes may be better than expected. Compared with what we
noted in previous studies,25 we did not observe higher response
rates to HMAs on the basis of the presence of TP53 mutations
independently of type of HMA, but patients with lower TP53 VAF
were more likely to respond to HMA therapy than those with higher
VAF. In addition, decrease in mutation burden was more frequently
observed among patients with clinical response to therapy. This
may be of particular importance when selecting optimal timing for
allo-SCT, particularly when considering the poor outcomes after
allo-SCT in TP53-mutant MDS and the impact of TP53 VAF in
outcomes after transplantation, as reported by other studies and as
observed in our study.31-34
Mutations in TP53 are known to predict for high risk of trans-
formation to AML.9 Although this process has traditionally been
assumed to be driven by TP53, in our study, we observed that
expansion of the TP53 mutant clone present at the time of MDS
diagnosis was associated with transformation only in a subset of
evaluated patients (61%). Emergence of clones harboring pre-
viously undetected mutations or cytogenetic abnormalities was
observed in 65% of patients, suggesting that the mechanisms of
transformation may not be exclusively related to TP53. To further
evaluate whether previous exposure to genotoxic therapy leading
to therapy-related disease could determine biological differences
in the mechanisms leading to transformation, we compared the
genomic changes from MDS diagnosis to the time of AML
transformation among de novo and T-MDS and could not identify
any differences in the frequency of TP53 clonal expansion or
acquisition of new mutations. However, this analysis is limited by the
small patient sample in which these data were available, and future
studies will be required to study this in further detail.
We acknowledge that our study has several limitations. First, our
sequencing technique did not include ultra-deep sequencing and
therefore small TP53mutations (VAF,1%) may have been missed;
we could not adjust for copy number changes to correct the
observed VAFs. Second, the panel of genes studied was not equal
among all included patients and sequencing of recurrently mutated
genes such as SF3B1, SRSF2, U2AF1, and ZRSR2 were studied
in only a subset of patients. Third, the retrospective nature of this
study limits our ability to unequivocally confirm the potential
prognostic impact of characteristics present in small patient
subsets or the potential role of allo-SCT in subgroups of patients
with TP53-mutated MDS. Prospective evaluation of patients with
TP53-mutated MDS with deep longitudinal sequencing will be
required to confirm our findings and study clonal evolution and
dynamics of TP53-mutated MDS in further detail. In addition, single-
cell sequencing in patients with multiple detectable TP53mutations
will be required to confirm the potential existence of biallelic TP53
mutations, and translational studies aimed at correlating specific
TP53 mutations or co-mutation patterns with distinct leukemogenic
potential will be required.
Despite these limitations, our data suggest that outcomes of
patients with MDS and TP53 mutations are not uniform and that
their response and prognosis may differ on the basis of mutation
burden and genomic context, even when correcting by clinical
characteristics. In addition, we identified that transformation to AML
in TP53-mutated MDS is not always associated with TP53 clone
expansion and that acquired or emerging clones at transformation
can be potentially targetable with available or emerging agents.
Finally, incorporation of this data at the time of diagnosis may allow
the definition of specific subgroups of patients with TP53-mutated
MDS and may help define the optimal therapeutic approach and
timing of transplantation.
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